Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31719858 | 1.00 | ROCK1 (0.34) | ROCK1IP6K1MEN1ALDH1A1KMT2A | |
| SCHEMBL31719833 | 1.00 | ROCK1 (0.34) | ROCK1IP6K1MEN1ALDH1A1KMT2A | |
| SCHEMBL30283623 | 0.85 | ROCK1 (0.39) | ROCK1IP6K1ALDH1A1PLCG1JAK3 | |
| SCHEMBL30283336 | 0.82 | ROCK1 (0.39) | ROCK1IP6K1ALDH1A1PLCG1 | |
| SCHEMBL30228010 | 0.80 | IGLV6-57 (0.43) | MEN1ALDH1A1KMT2A | |
| SCHEMBL30228409 | 0.80 | IGLV6-57 (0.43) | MEN1ALDH1A1KMT2A | |
| SCHEMBL31731467 | 0.79 | PIK3CD (0.36) | MEN1ALDH1A1KMT2A | |
| SCHEMBL31731586 | 0.79 | PIK3CD (0.36) | MEN1ALDH1A1KMT2A | |
| SCHEMBL30283445 | 0.79 | ROCK1 (0.37) | ROCK1IP6K1ALDH1A1PLCG1JAK3 | |
| SCHEMBL30283587 | 0.78 | ALDH1A1 (0.41) | ROCK1IP6K1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | POLRMT, TFAM, UQCRC1 | ROCK1 3060/4885IP6K1 1594/4885MEN1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.